
The Untapped Potential of Ensitrelvir: A Superior COVID Treatment Overlooked in America
Americans are unable to access ensitrelvir, a superior antiviral drug to Paxlovid, due to delays in the FDA approval process. Ensitrelvir, marketed as Xocova in Japan, offers advantages such as faster recovery time, fewer rebound infections, and a more tolerable taste. However, experts predict that ensitrelvir won't be available in the US until the end of 2024. While the FDA has granted the drug "fast-track" status, it is unlikely to receive emergency-use authorization like Paxlovid. Ensitrelvir has shown promise in reducing the loss of smell and taste associated with COVID-19. Clinical trials are ongoing to further evaluate its safety and effectiveness.
